Download Library

Download Library

Document Type
Efficacy of DRd Versus Rd for Relapsed or Refractory MM: Updated Analysis of Pollux - ASH abstract - November 2016 (Moreau)
Efficacy of DRd Versus Rd for Relapsed or Refractory MM: Updated Analysis of Pollux - ASH abstract - November 2016 (Moreau)
Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH abstract - November 2016 (Caillon)
Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH abstract - November 2016 (Caillon)
Cost-Effectiveness Analysis of Ofatumumab as a Treatment for Relapsed CLL in the United States - ASH abstract - November 2016 (Tremblay)
Cost-Effectiveness Analysis of Ofatumumab as a Treatment for Relapsed CLL in the United States - ASH abstract - November 2016 (Tremblay)
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH abstract - November 2016 (Hájek)
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH abstract - November 2016 (Hájek)
Clinical Efficacy of Daratumumab, Pomalidomide & Dexamethasone in Relapsed, Refractory Myeloma: Utility of Retreatment with Daratumumab Among Refractory Patients - ASH abstract - November 2016 (Nooka)
Clinical Efficacy of Daratumumab, Pomalidomide & Dexamethasone in Relapsed, Refractory Myeloma: Utility of Retreatment with Daratumumab Among Refractory Patients - ASH abstract - November 2016 (Nooka)
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH abstract - November 2016 (Usmani)
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH abstract - November 2016 (Usmani)
Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari)
Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari)
Efficacy of DVd Versus Vd in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor - ASH abstract - November 2016 (Mateos)
Efficacy of DVd Versus Vd in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor - ASH abstract - November 2016 (Mateos)
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH abstract - November 2016 (Avet-Loiseau)
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH abstract - November 2016 (Avet-Loiseau)
Q3 2016 Results Presentation
Q3 2016 Results Presentation
Bank of America Merrill Lynch Global Healthcare Conference, London, UK - September 2016
Bank of America Merrill Lynch Global Healthcare Conference, London, UK - September 2016
Q3 2016 Results Podcast
Q3 2016 Results Podcast
Interim Report First Half 2016
Interim Report First Half 2016
First Half 2016 Results Presentation
First Half 2016 Results Presentation
First Half 2016 Results Podcast
First Half 2016 Results Podcast
Daratumumab monotherapy compared with real-world control data in heavily pretreated patients with multiple myeloma - EHA E-Poster - June 2016 (Diels)
Daratumumab monotherapy compared with real-world control data in heavily pretreated patients with multiple myeloma - EHA E-Poster - June 2016 (Diels)
Cost per median overall month of survival in multiple myeloma patients with greater than or equal to 3 lines of therapy - ASCO poster - June 2016 (Maiese)
Cost per median overall month of survival in multiple myeloma patients with greater than or equal to 3 lines of therapy - ASCO poster - June 2016 (Maiese)
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study
Pharmacodynamic relationship between natural killer cells and daratumumab exposure in multiple myeloma - EHA Poster - June 2016 (Casneuf)
Pharmacodynamic relationship between natural killer cells and daratumumab exposure in multiple myeloma - EHA Poster - June 2016 (Casneuf)
Daratumumab plus bortezomib & dexamethasone Phase 3 CASTOR data - ASCO presentation - June 2016 (Palumbo)
Daratumumab plus bortezomib & dexamethasone Phase 3 CASTOR data - ASCO presentation - June 2016 (Palumbo)
Goldman Sachs 37th Annual Global Healthcare Conference, Rancho Palos Verdes, CA, US - June 2016
Goldman Sachs 37th Annual Global Healthcare Conference, Rancho Palos Verdes, CA, US - June 2016
Daratumumab plus Lenalidomide & dexamethasone Phase 3 POLLUX data - EHA presentation - June 2016 (Dimopoulos)
Daratumumab plus Lenalidomide & dexamethasone Phase 3 POLLUX data - EHA presentation - June 2016 (Dimopoulos)
Phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in multiple myeloma (PAVO) - ASCO poster - June 2016 (Nahi)
Phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in multiple myeloma (PAVO) - ASCO poster - June 2016 (Nahi)
Interim Report First Quarter 2016
Interim Report First Quarter 2016
Ofatumumab vs rituximab Phase 3 HOMER data - EHA abstract - May 2016 (Maloney)
Ofatumumab vs rituximab Phase 3 HOMER data - EHA abstract - May 2016 (Maloney)
Daratumumab monotherapy compared with real-world control data in heavily pretreated patients with multiple myeloma - EHA abstract - May 2016 (Casneuf)
Daratumumab monotherapy compared with real-world control data in heavily pretreated patients with multiple myeloma - EHA abstract - May 2016 (Casneuf)